159 related articles for article (PubMed ID: 36542412)
21. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes.
Kapoor D; Clarke S; Stanworth R; Channer KS; Jones TH
Eur J Endocrinol; 2007 May; 156(5):595-602. PubMed ID: 17468196
[TBL] [Abstract][Full Text] [Related]
22. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
23. [Testosterone Undecanoate Pills improves insulin resistance in type-2 diabetes men with hypogonadism].
DI HJ; Fan YF; Zhang HF; Liu KM; Liu C
Zhonghua Nan Ke Xue; 2017 Jun; 23(6):517-521. PubMed ID: 29722943
[TBL] [Abstract][Full Text] [Related]
24. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
Hackett G
Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
[TBL] [Abstract][Full Text] [Related]
25. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
[TBL] [Abstract][Full Text] [Related]
26. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
27. Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism.
Sonmez A; Haymana C; Bolu E; Aydogdu A; Tapan S; Serdar M; Altun B; Barcin C; Taslipinar A; Meric C; Uckaya G; Kutlu M
Eur J Endocrinol; 2011 May; 164(5):759-64. PubMed ID: 21325471
[TBL] [Abstract][Full Text] [Related]
28. Testosterone therapy preserves muscle strength and power in aging men with type 2 diabetes-a randomized controlled trial.
Magnussen LV; Hvid LG; Hermann AP; Hougaard DM; Gram B; Caserotti P; Andersen MS
Andrology; 2017 Sep; 5(5):946-953. PubMed ID: 28914503
[TBL] [Abstract][Full Text] [Related]
29. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
Haider A; Saad F; Doros G; Gooren L
Obes Res Clin Pract; 2014; 8(4):e339-49. PubMed ID: 25091355
[TBL] [Abstract][Full Text] [Related]
30. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).
Isidori AM; Aversa A; Calogero A; Ferlin A; Francavilla S; Lanfranco F; Pivonello R; Rochira V; Corona G; Maggi M
J Endocrinol Invest; 2022 Dec; 45(12):2385-2403. PubMed ID: 36018454
[TBL] [Abstract][Full Text] [Related]
31. Type 2 diabetes mellitus and testosterone: a meta-analysis study.
Corona G; Monami M; Rastrelli G; Aversa A; Sforza A; Lenzi A; Forti G; Mannucci E; Maggi M
Int J Androl; 2011 Dec; 34(6 Pt 1):528-40. PubMed ID: 20969599
[TBL] [Abstract][Full Text] [Related]
32. Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment.
Gianatti EJ; Grossmann M
Diabet Med; 2020 Feb; 37(2):174-186. PubMed ID: 31006133
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes.
Corona G; Rastrelli G; Maggi M
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):557-79. PubMed ID: 24054931
[TBL] [Abstract][Full Text] [Related]
34. Androgens and male sexual function.
Corona G; Rastrelli G; Vignozzi L; Maggi M
Best Pract Res Clin Endocrinol Metab; 2022 Jul; 36(4):101615. PubMed ID: 35153145
[TBL] [Abstract][Full Text] [Related]
35. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
[TBL] [Abstract][Full Text] [Related]
36. Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups.
Ramachandran S; Hackett GI; Strange RC
Andrology; 2020 Sep; 8(5):1222-1232. PubMed ID: 32384175
[TBL] [Abstract][Full Text] [Related]
37. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
38. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
[TBL] [Abstract][Full Text] [Related]
39. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.
Dhindsa S; Ghanim H; Batra M; Kuhadiya ND; Abuaysheh S; Sandhu S; Green K; Makdissi A; Hejna J; Chaudhuri A; Punyanitya M; Dandona P
Diabetes Care; 2016 Jan; 39(1):82-91. PubMed ID: 26622051
[TBL] [Abstract][Full Text] [Related]
40. Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.
Colleluori G; Aguirre L; Napoli N; Qualls C; Villareal DT; Armamento-Villareal R
J Clin Endocrinol Metab; 2021 Jul; 106(8):e3058-e3068. PubMed ID: 33735389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
